148 related articles for article (PubMed ID: 16432707)
1. In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100.
Das S; Shahmanesh M; Stolinski M; Shojaee-Moradie F; Jefferson W; Jackson NC; Cobbold M; Nightingale P; Umpleby AM
Diabetologia; 2006 Mar; 49(3):538-42. PubMed ID: 16432707
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.
Shahmanesh M; Das S; Stolinski M; Shojaee-Moradie F; Jackson NC; Jefferson W; Cramb R; Nightingale P; Umpleby AM
J Clin Endocrinol Metab; 2005 Feb; 90(2):755-60. PubMed ID: 15522931
[TBL] [Abstract][Full Text] [Related]
3. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
Zulewski H; Ninnis R; Miserez AR; Baumstark MW; Keller U
J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
[TBL] [Abstract][Full Text] [Related]
4. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
Millar JS; Lichtenstein AH; Cuchel M; Dolnikowski GG; Hachey DL; Cohn JS; Schaefer EJ
J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
7. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
8. Influence of obesity on the metabolism of apolipoprotein B in humans.
Egusa G; Beltz WF; Grundy SM; Howard BV
J Clin Invest; 1985 Aug; 76(2):596-603. PubMed ID: 4031064
[TBL] [Abstract][Full Text] [Related]
9. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
[TBL] [Abstract][Full Text] [Related]
11. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study.
Petit JM; Duong M; Florentin E; Duvillard L; Chavanet P; Brun JM; Portier H; Gambert P; Verges B
J Lipid Res; 2003 Sep; 44(9):1692-7. PubMed ID: 12869587
[TBL] [Abstract][Full Text] [Related]
12. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?
Ng TW; Watts GF; Farvid MS; Chan DC; Barrett PH
Diabetes; 2005 Mar; 54(3):795-802. PubMed ID: 15734858
[TBL] [Abstract][Full Text] [Related]
13. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
14. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase.
Pacy PJ; Mitropoulos KA; Venkatesan S; Watts GF; Reeves BE; Halliday D
Atherosclerosis; 1993 Nov; 103(2):231-43. PubMed ID: 8292098
[TBL] [Abstract][Full Text] [Related]
16. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
[TBL] [Abstract][Full Text] [Related]
17. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males.
Sumner AE; Falkner B; Diffenderfer MR; Barrett PH; Marsh JB
Proc Soc Exp Biol Med; 1999 Sep; 221(4):352-60. PubMed ID: 10460697
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
20. Multiple changes in apoprotein B containing lipoproteins after ethanol withdrawal in alcoholic men.
Kervinen K; Savolainen MJ; Kesäniemi YA
Ann Med; 1991 Oct; 23(4):407-13. PubMed ID: 1930937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
